Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 29 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pioglitazone Open Label Clear all
Completed Phase 2 Interventional Results available

Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL

NCT00300365
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pioglitazone, Placebo, Niacin ER, Aspirin
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

NCT00671515
View directory record Official record
Conditions
Depressive Disorder, Major, Metabolic Syndrome X
Interventions
Pioglitazone
Drug
Lead sponsor
Joseph Calabrese, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

NCT00839527
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
placebo to match albiglutide, albiglutide, metformin, glimepiride, pioglitazone, placebo to match pioglitazone
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
321
States / cities
Alabaster, Alabama • Birmingham, Alabama • Dothan, Alabama + 257 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Terminated Phase 2 Interventional

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

NCT00229684
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Tesaglitazar, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
45 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2011 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

NCT00295633
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Saxagliptin, Placebo, pioglitazone, rosiglitazone, metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
79
States / cities
Haleyville, Alabama • Mobile, Alabama • Ozark, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Study of Pioglitazone in Sporadic Inclusion Body Myositis

NCT03440034
View directory record Official record
Conditions
Myositis, Inclusion Body Myositis, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases
Interventions
Pioglitazone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional

Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.

NCT00672919
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
51
States / cities
Birmingham, Alabama • Tucson, Arizona • Bellflower, California + 48 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Characterize the Effect on the Pharmacokinetics of ASP1941 and Pioglitazone Hydrochloride When Given Together to Healthy Subjects

NCT01088919
View directory record Official record
Conditions
Healthy, Pharmacokinetics of ASP1941
Interventions
ASP1941, pioglitazone hydrochloride
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2010 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
vildagliptin, thiazolidinedione (TZD)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,665 participants
Timeline
Started 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.

NCT00545233
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
peginterferon alfa-2a [Pegasys], ribavirin [Copegus], Pioglitazone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
65
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2012 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Pioglitazone

NCT04671056
View directory record Official record
Conditions
Healthy
Interventions
MGL-3196, Pioglitazone 15mg
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects

NCT01309854
View directory record Official record
Conditions
Rheumatoid Arthritis, Healthy Volunteers, Pharmacokinetics, Pioglitazone, Drug-drug Interaction, Amount of Pioglitazone in Blood
Interventions
fostamatinib, pioglitazone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes

NCT00097279
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
biphasic insulin aspart, pioglitazone, metformin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Terminated Phase 4 Interventional Results available

Fatty Liver Study in Patients With Type II Diabetes

NCT02365233
View directory record Official record
Conditions
Type II Diabetes, Nonalcoholic Fatty Liver
Interventions
DPP4 inhibitor, Pioglitazone, Lantus insulin
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

NCT02342067
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Pioglitazone
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated May 12, 2015 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)

NCT00994682
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Interventions
Pioglitazone study drug, Placebo, Pioglitazone Open Label
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)

NCT02222441
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NCT00972283
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,006 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
66
States / cities
Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional

Study of NGM313 in Obese Participants

NCT03298464
View directory record Official record
Conditions
Obese
Interventions
NGM313, Pioglitazone
Biological · Drug
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

NCT03457597
View directory record Official record
Conditions
Healthy
Interventions
Midazolam hydrochloride, Metoprolol tartrate, Pioglitazone hydrochloride, Tolbutamide, Omeprazole, Relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional

GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study

NCT04473274
View directory record Official record
Conditions
Coronavirus Infection, Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
Samaritan Health Services
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers

NCT02371603
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 25 mg Tablet, Pioglitazone 15 mg Tablet, Rosuvastatin 10 mg Tablet, Trimethoprim 100 mg Tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 2:56 PM EDT